Protocol
RST332: Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Diseases
Solid Tumor : Non-rhabdomyosarcoma soft tissue sarcomas
Description
Participants in this research study have a type of cancer called non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). NRSTS includes tumors such as synovial sarcoma, malignant peripheral nerve sheath tumor, undifferentiated sarcoma, epithelioid sarcoma, fibrosarcoma, and liposarcoma. NRSTS are rare tumors and little is known about them. Physicians want to develop better treatments for these tumors. The information available about treating these tumors suggests that the amount of treatment needed may be associated with the “risk group” of the tumor. Patients are assigned to a risk group based on the characteristics of cells in the tumor, the size of the tumor, whether the tumor has spread into other areas of the body, and how much of the tumor may be taken out by surgery.
Participants with low-risk tumors may be cured with mild treatment: surgically removing the tumor, with or without radiation therapy (high-energy X-ray therapy). Intermediate and high-risk tumors may need more treatment, including chemotherapy (anti-cancer drugs) and radiation therapy. Treatments with chemotherapy or radiation therapy may cause bad effects that occur later in life.
There are four different treatment groups in this research study. Each group is based on the risk group of the tumor. Participants will have had either surgery to remove the tumor or a biopsy of the tumor before entry into this research study. The study goal is to evaluate new risk-based treatments, while limiting the possibility of bad effects and increasing the effectiveness of therapies for non-rhabdomyosarcoma soft tissue sarcomas.
Objectives
Eligibility
- Participant is less than 30 years of age at the time of the histological confirmation of non-rhabdomyosarcoma soft tissue sarcoma
- Participant is able to perform ordinary tasks and daily activities as defined in the study guidelines
- Participant meets other requirements defined in the eligibility portion of the study
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Contact
Sheri Spunt, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
FAX: 901-595-5068
Referring or consulting physicians only: protocolinfo@stjude.org
For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.